The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Preventing and Treating Bone Metastases in mCRPC
April 30th 2016Bone metastases in metastatic castration-resistant prostate cancer can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.
CHMP Grants Positive Opinion for Bevacizumab/Erlotinib Combo in NSCLC
April 29th 2016The Committee for Medicinal Products for Human Use has recommended the first-line approval of bevacizumab (Avastin) in combination with erlotinib (Tarceva) for patients with advanced or metastatic EGFR-mutant non–small cell lung cancer.
CHMP Recommends Approval of Obinutuzumab for Follicular Lymphoma
April 29th 2016Obinutuzumab (Gazyva) has received a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use for use in combination with bendamustine as a treatment for patients with follicular lymphoma who previously received chemotherapy.
CHMP Recommends Approval of Everolimus for GI, Lung NETs
April 29th 2016Everolimus (Afinitor) has received a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use as a treatment for patients with progressive, unresectable or metastatic, well-differentiated nonfunctional gastrointestinal or lung neuroendocrine tumors.
Perou Shares How Deeper Sequencing of Genome Helps Define, Treat Breast Cancer Subtypes
April 28th 2016Charles M. Perou, PhD, discusses how lobular breast cancer subtypes are used in clinical practice, what researchers have learned from sequencing the genome, and how determining intrinsic subtypes can help guide breast cancer therapy.
NEJM Data Illuminate Efficacy of Oral Ixazomib Triplet in Myeloma
April 28th 2016Adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression or death by 26% compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.
IDO Inhibitor/Chemo Combo Shows Early Promise in Advanced Pancreatic Cancer
April 27th 2016Nathan Bahary, MD, discusses results of a study that showed that the combination of indoximod with standard chemotherapy yielded a response rate of 42% as a first-line therapy for patients with metastatic pancreatic adenocarcinoma.
Radium-223 May Enhance Immune Response With Sipuleucel-T in mCRPC
April 26th 2016Jong Chul Park, MD, discusses the potential synergy of radium-223 and sipuleucel-T, which is being investigated in a clinical trial as a potential treatment for patients with metastatic castration-resistant prostate cancer.
Pancreatic Cancer Risk Tied to Specific Mouth Bacteria
April 26th 2016The presence of certain bacteria in the mouth may reveal increased risk for pancreatic cancer and enable earlier, more precise treatment. This is the main finding of a study led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center.
FDA Grants Nivolumab Breakthrough Designation for Head and Neck Cancer
April 25th 2016The FDA has granted a breakthrough therapy designation to nivolumab as a single-agent treatment for patients with recurrent or metastatic squamous cell carcinoma of the head and neck following a platinum-based therapy.
Analysis of Real-World Data for Next-Generation Antiandrogen Therapies
April 25th 2016Real-world data obtained from large retrospective studies can also deliver useful insights into the clinical challenges associated with newer therapies in prostate cancer, such as medication adherence and cognitive adverse events.
Optimal Sequencing Explored for Enzalutamide and Abiraterone in mCRPC
April 22nd 2016Although abiraterone acetate (Zytiga) and enzalutamide (Xtandi) have demonstrated improved survival outcomes, the optimal sequencing of these therapies has not been established, and most patients exhibit some degree of cross-resistance.
Frontline Palbociclib Extends PFS in Phase III Breast Cancer Study
April 19th 2016The phase III PALOMA-2 trial has shown a significant improvement in progression-free survival for the frontline combination of palbociclib and letrozole compared letrozole alone for patients with ER-positive, HER2-negative advanced or metastatic breast cancer.